Log in

NASDAQ:PRNBPrincipia Biopharma Stock Price, Forecast & News

$63.89
-0.45 (-0.70 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$61.02
Now: $63.89
$64.62
50-Day Range
$57.42
MA: $63.27
$69.00
52-Week Range
$25.35
Now: $63.89
$75.65
Volume381,045 shs
Average Volume236,919 shs
Market Capitalization$2.11 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.66
Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.
Read More
Principia Biopharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.18 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRNB
CUSIPN/A
CIKN/A
Phone650-416-7700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$35.16 million
Book Value$10.03 per share

Profitability

Net Income$-53,790,000.00

Miscellaneous

Employees65
Market Cap$2.11 billion
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive PRNB News and Ratings via Email

Sign-up to receive the latest news and ratings for PRNB and its competitors with MarketBeat's FREE daily newsletter.

Principia Biopharma (NASDAQ:PRNB) Frequently Asked Questions

How has Principia Biopharma's stock been impacted by COVID-19 (Coronavirus)?

Principia Biopharma's stock was trading at $53.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PRNB shares have increased by 18.6% and is now trading at $63.89. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Principia Biopharma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Principia Biopharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Principia Biopharma.

When is Principia Biopharma's next earnings date?

Principia Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Principia Biopharma.

How were Principia Biopharma's earnings last quarter?

Principia Biopharma Inc (NASDAQ:PRNB) posted its quarterly earnings data on Wednesday, May, 6th. The company reported ($0.99) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.79) by $0.20. View Principia Biopharma's earnings history.

What price target have analysts set for PRNB?

5 brokers have issued twelve-month price objectives for Principia Biopharma's stock. Their forecasts range from $76.00 to $82.00. On average, they anticipate Principia Biopharma's share price to reach $78.60 in the next twelve months. This suggests a possible upside of 23.0% from the stock's current price. View analysts' price targets for Principia Biopharma.

Has Principia Biopharma been receiving favorable news coverage?

Press coverage about PRNB stock has trended somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Principia Biopharma earned a news sentiment score of 2.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutPrincipia Biopharma.

Who are some of Principia Biopharma's key competitors?

What other stocks do shareholders of Principia Biopharma own?

Who are Principia Biopharma's key executives?

Principia Biopharma's management team includes the following people:
  • Dr. Alan B. Colowick Ph.D., M.D., M.P.H., Exec. Chairman (Age 57)
  • Mr. Martin Babler, CEO & Director (Age 54)
  • Mr. Christopher Y. Chai, Chief Financial Officer (Age 52)
  • Ms. Stefani A. Wolff, Chief Devel. Officer (Age 57)
  • Dr. David M. Goldstein, Chief Scientific Officer (Age 53)

When did Principia Biopharma IPO?

(PRNB) raised $75 million in an initial public offering on Friday, September 14th 2018. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, Leerink Partners and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.

What is Principia Biopharma's stock symbol?

Principia Biopharma trades on the NASDAQ under the ticker symbol "PRNB."

Who are Principia Biopharma's major shareholders?

Principia Biopharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Redmile Group LLC (6.84%), Cormorant Asset Management LP (6.36%), BlackRock Inc. (5.93%), Wellington Management Group LLP (4.87%), State Street Corp (1.98%) and Pictet Asset Management Ltd. (1.37%). Company insiders that own Principia Biopharma stock include Alan Colowick, Christopher Y Chai, Daniel J Becker, David Goldstein, David M Goldstein, Dolca Thomas, Leaf Ventures Ii LP New, Martin Babler, Orbimed Advisors Llc, Plc Glaxosmithkline, Roy C Hardiman, Simeon George, Srinivas Akkaraju and Stefani Wolff. View institutional ownership trends for Principia Biopharma.

Which major investors are selling Principia Biopharma stock?

PRNB stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Redmile Group LLC, Nuveen Asset Management LLC, Pictet Asset Management Ltd., Massachusetts Financial Services Co. MA, JPMorgan Chase & Co., Alliancebernstein L.P., and AXA. Company insiders that have sold Principia Biopharma company stock in the last year include Alan Colowick, Christopher Y Chai, David Goldstein, David M Goldstein, Dolca Thomas, Leaf Ventures Ii LP New, Martin Babler, Roy C Hardiman, and Stefani Wolff. View insider buying and selling activity for Principia Biopharma.

Which major investors are buying Principia Biopharma stock?

PRNB stock was bought by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Cormorant Asset Management LP, BlackRock Inc., Aviva PLC, First Trust Advisors LP, State Street Corp, Grantham Mayo Van Otterloo & Co. LLC, and Two Sigma Investments LP. Company insiders that have bought Principia Biopharma stock in the last two years include Daniel J Becker, Leaf Ventures Ii LP New, Plc Glaxosmithkline, Simeon George, and Srinivas Akkaraju. View insider buying and selling activity for Principia Biopharma.

How do I buy shares of Principia Biopharma?

Shares of PRNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Principia Biopharma's stock price today?

One share of PRNB stock can currently be purchased for approximately $63.89.

How big of a company is Principia Biopharma?

Principia Biopharma has a market capitalization of $2.11 billion and generates $35.16 million in revenue each year. The company earns $-53,790,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis. Principia Biopharma employs 65 workers across the globe.

What is Principia Biopharma's official website?

The official website for Principia Biopharma is www.principiabio.com.

How can I contact Principia Biopharma?

Principia Biopharma's mailing address is 220 East Grand Avenue, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-416-7700 or via email at [email protected]

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.